» Articles » PMID: 37240683

High Risk for Persistent Peri-Prosthetic Infection and Amputation in Mega-Prosthesis Reconstruction

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 May 27
PMID 37240683
Authors
Affiliations
Soon will be listed here.
Abstract

A peri-prosthetic joint infection is a feared complication after mega-prosthesis reconstruction of large bone defects. The current study investigates how patients operated with a mega-prosthesis due to sarcoma, metastasis, or trauma, are affected by a deep infection focusing on re-operations, risk for persistent infection, arthrodesis, or subsequent amputation. Time to infection, causative bacterial strains, mode of treatment and length of hospital stay are also reported. A total of 114 patients with 116 prostheses were evaluated, a median of 7.6 years (range 3.8-13.7) after surgery, of which 35 (30%) were re-operated due to a peri-prosthetic infection. Of the infected patients, the prosthesis was still in place in 51%, 37% were amputated, and 9% had an arthrodesis. The infection was persistent in 26% of the infected patients at follow-up. The mean total length of hospital stay was 68 (median 60) days and the mean number of reoperations was 8.9 (median 6.0). The mean length of antibiotic treatment was 340 days (median 183). Coagulase-negative staphylococci and were the most frequent bacterial agents isolated in deep cultures. No MRSA- or ESBL-producing were found but vancomycin-resistant was isolated in one patient. In summary, there is a high risk for peri-prosthetic infection in mega-prostheses, resulting in persistent infection or amputation relatively often.

Citing Articles

Amputation Triggers Long-Range Epidermal Permeability Changes in Evolutionarily Distant Regenerative Organisms.

Dooling K, Kim R, Kim E, Chen E, Abouelela A, Tajer B bioRxiv. 2024; .

PMID: 39257748 PMC: 11383696. DOI: 10.1101/2024.08.29.610385.


Characteristics and Epidemiology of Megaprostheses Infections: A Systematic Review.

Cianni L, Taccari F, Bocchi M, Micheli G, Sangiorgi F, Ziranu A Healthcare (Basel). 2024; 12(13).

PMID: 38998818 PMC: 11241048. DOI: 10.3390/healthcare12131283.


Surgical Management of Periprosthetic Joint Infections in Hip and Knee Megaprostheses.

Theil C, Bockholt S, Gosheger G, Dieckmann R, Schwarze J, Schulze M Medicina (Kaunas). 2024; 60(4).

PMID: 38674229 PMC: 11051768. DOI: 10.3390/medicina60040583.

References
1.
Berger C, Larsson S, Bergh P, Brisby H, Wennergren D . The risk for complications and reoperations with the use of mega prostheses in bone reconstructions. J Orthop Surg Res. 2021; 16(1):598. PMC: 8515693. DOI: 10.1186/s13018-021-02749-z. View

2.
Holm C, Bardram C, Riecke A, Horstmann P, Petersen M . Implant and limb survival after resection of primary bone tumors of the lower extremities and reconstruction with mega-prostheses fifty patients followed for a mean of forteen years. Int Orthop. 2018; 42(5):1175-1181. DOI: 10.1007/s00264-018-3861-7. View

3.
Bus M, van de Sande M, Fiocco M, Schaap G, Bramer J, Dijkstra P . What Are the Long-term Results of MUTARS Modular Endoprostheses for Reconstruction of Tumor Resection of the Distal Femur and Proximal Tibia?. Clin Orthop Relat Res. 2015; 475(3):708-718. PMC: 5289150. DOI: 10.1007/s11999-015-4644-8. View

4.
Thornley P, Evaniew N, Riediger M, Winemaker M, Bhandari M, Ghert M . Postoperative antibiotic prophylaxis in total hip and knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. CMAJ Open. 2015; 3(3):E338-43. PMC: 4596117. DOI: 10.9778/cmajo.20150012. View

5.
Morgan H, Cizik A, Leopold S, Hawkins D, Conrad 3rd E . Survival of tumor megaprostheses replacements about the knee. Clin Orthop Relat Res. 2006; 450:39-45. DOI: 10.1097/01.blo.0000229330.14029.0d. View